ORKA Stock Forecast & Price Target

Oruka Therapeutics is supported by compelling Phase 2b EVERLAST-B data that replicated EVERLAST-A, with 600 mg ORKA-001 delivering 61% PASI-100 and 86% PASI-90 at 16 weeks, while safety remained clean and showed no new infection signal. The key fundamental thesis is that ORKA-001’s ~100-day half-life and strong response durability could enable Q12M maintenance dosing, creating a differentiated convenience profile alongside best-in-class efficacy versus leading IL-23 competitors. ORKA-002 adds further upside with a 75-80 day half-life, Q6M/Q3M modeled dosing potential, and expansion into PsO, HS, and other I&I indications, while valuation is underpinned by estimated ~$7B peak sales for ORKA-001 and a sum-of-parts framework.

Oruka Therapeutics is a high-risk clinical-stage biotech with no approved products, so its valuation depends on uncertain outcomes in ORKA-001 and ORKA-002 rather than recurring revenue or proven commercial demand. The company faces meaningful regulatory and clinical execution risk, including the possibility of delayed trials, failed studies across PsO, HS, and other indications, unexpected safety issues, and regulators requiring additional data or narrower labels that could weaken market adoption. Financially, it will need access to capital markets to fund development and commercialization, and if it cannot raise adequate funds before becoming cash flow positive, dilution or a funding shortfall could materially impair progress.